Form 4: PTC Therapeutics Exec Sells Shares After Option Exercise

A PTC Therapeutics executive exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 plan.

Summary

• Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, Inc. (PTCT), reported transactions involving the company's common stock.
• On October 7, 2025, Boulding exercised stock options to acquire 3,375 shares of common stock at an exercise price of $38.1 per share.
• Concurrently, Boulding sold a total of 3,375 shares of common stock in multiple transactions on October 7, 2025.
• The sales occurred at weighted average prices of $62.89 (1,757 shares), $63.8 (1,306 shares), and $64.97 (312 shares).
• All reported transactions were executed pursuant to a Rule 10b5-1 plan adopted by Boulding on December 5, 2024.
• Following these transactions, Boulding directly beneficially owns 103,901 shares of common stock and 3,376 stock options.
• The exercised option was granted on January 7, 2022, and vests over four years, with 25% vesting on January 7, 2023, and 6.25% vesting quarterly thereafter.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan, which is generally considered neutral as it reflects scheduled compensation activity rather than a change in sentiment about the company's prospects.

Positives

• The executive realized a significant profit by exercising options at $38.1 and selling shares at weighted average prices ranging from $62.89 to $64.97, indicating a healthy return on vested equity.

Negatives

• The sale of 3,375 shares reduces the executive's direct beneficial ownership of common stock, though this is a common practice following option exercises.

Future Outlook

This Form 4 filing does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an executive's past transactions.

Management Comments

• The transactions were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Industry Context

The reported transactions are typical for executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, where stock options form a significant part of compensation packages. The use of a Rule 10b5-1 plan is a standard practice to allow insiders to sell shares in a pre-arranged manner, mitigating concerns about trading on material non-public information.

Comparison to Industry Standards

• The exercise of stock options and subsequent sale of shares is a common component of executive compensation across various industries, including biotech, and aligns with standard practices for monetizing equity incentives.
• The execution of these transactions under a Rule 10b5-1 plan is a widely adopted corporate governance practice, demonstrating adherence to insider trading regulations and providing transparency regarding pre-scheduled sales, similar to practices at comparable companies in the pharmaceutical sector.

Related Party Transactions

• The reported transactions involve an executive (Mark Elliott Boulding) of PTC Therapeutics, Inc. trading in the company's securities, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The exercise of options and subsequent sale of shares by an executive is a routine event and typically has minimal direct impact on existing shareholders, as it is part of executive compensation and pre-planned.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The remaining unexercised stock options will continue to vest according to the established schedule, with 6.25% of the original number of shares vesting at the end of each successive three-month period.

Key Dates

Recommendation

This Form 4 details a routine, pre-scheduled insider transaction (option exercise and sale) by an executive. Such transactions, executed under a 10b5-1 plan, are typically not indicative of new material information or a change in the executive's outlook on the company's future. Therefore, it does not provide a basis for a change in investment recommendation, suggesting a 'hold' position remains appropriate based solely on this filing.

Keywords

PTC Therapeutics, PTCT, Insider Transaction, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation